Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 113 articles: HTML format Text format

Single Articles

July 2019
1. KUDO Y, Haymaker C, Zhang J, Reuben A, et al
   Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer.
   Ann Oncol. 2019 Jul 8. pii: 5529670. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   June 2019
2. FRUH M, Peters S
   EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in Non-Small Cell Lung Cancer.
   Ann Oncol. 2019 Jun 14. pii: 5518918. doi: 10.1093.
   PubMed     Text format    
   
   
   
3. PASTORINO U, Silva M, Sestini S, Sabia F, et al
   Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy.
   Ann Oncol. 2019 Jun 5. pii: 5511622. doi: 10.1093.
   PubMed     Text format    
   
   
   May 2019
4. MAZIERES J, Drilon A, Lusque A, Mhanna L, et al
   Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
   Ann Oncol. 2019 May 24. pii: 5498206. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
5. HASTINGS K, Yu H, Wei W, Sanchez-Vega F, et al
   EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.
   Ann Oncol. 2019 May 14. pii: 5488949. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
6. KELLY RJ, Shepherd FA, Krivoshik A, Jie F, et al
   A Phase 3, Randomized, Open-label Study of ASP8273 Versus Erlotinib or Gefitinib in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer.
   Ann Oncol. 2019 May 9. pii: 5487410. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
7. ROTA M, Pizzato M, La Vecchia C, Boffetta P, et al
   Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis.
   Ann Oncol. 2019 May 2. pii: 5482568. doi: 10.1093.
   PubMed     Text format    
   
   
   April 2019
8. TAY RY, Fernandez-Gutierrez F, Foy V, Burns K, et al
   Prognostic value of circulating tumour cells in limited-stage small cell lung cancer: analysis of the concurrent ONce-daily versus twice-daily RadioTherapy (CONVERT) randomised controlled trial.
   Ann Oncol. 2019 Apr 24. pii: 5479461. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
9. SHAW AT, Riely GJ, Bang YJ, Kim DW, et al
   Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
   Ann Oncol. 2019 Apr 13. pii: 5448502. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
10. KIM CG, Kim KH, Pyo KH, Xin CF, et al
    Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Ann Oncol. 2019 Apr 12. pii: 5448854. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
11. PASTORINO U, Silva M, Sestini S, Sabia F, et al
    Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial.
    Ann Oncol. 2019 Apr 1. pii: 5425325. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    March 2019
12. PETERS S, Reck M, Smit EF, Mok T, et al
    How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.
    Ann Oncol. 2019 Mar 26. pii: 5420157. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
13. HANNIGAN B, Ye W, Mehrotra M, Lam V, et al
    Liquid Biopsy Assay for Lung Carcinoma Using Centrifuged Supernatants from Fine Needle Aspiration Specimens.
    Ann Oncol. 2019 Mar 18. pii: 5384494. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    February 2019
14. BLUMENTHAL GM, Gong Y, Kehl K, Mishra-Kalyani P, et al
    Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in clinical trials of patients with non-small cell lung cancer.
    Ann Oncol. 2019 Feb 22. pii: 5362014. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
15. WIESWEG M, Mairinger F, Reis H, Goetz M, et al
    Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small cell lung cancer.
    Ann Oncol. 2019 Feb 11. pii: 5315508. doi: 10.1093.
    PubMed     Text format    
    
    
    
16. MORABITO A
    Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!
    Ann Oncol. 2019 Feb 2. pii: 5306111. doi: 10.1093.
    PubMed     Text format    
    
    
    
17. AMARAL SR, Casal Moura M, Carvalho J, Chaves A, et al
    6PPrognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors.
    Ann Oncol. 2019;30.
    PubMed     Text format    
    
    
    
18. WANG M, Ma X
    26PTexture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy.
    Ann Oncol. 2019;30.
    PubMed     Text format    
    
    
    
19. XIE Y
    35PEnhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7.
    Ann Oncol. 2019;30.
    PubMed     Text format    
    
    
    January 2019
20. ZUO H, Ueland PM, Midttun O, Tell GS, et al
    Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3).
    Ann Oncol. 2019 Jan 30. pii: 5304407. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
21. PLANCHARD D, Popat S, Kerr K, Novello S, et al
    Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jan 30. pii: 5304567. doi: 10.1093.
    PubMed     Text format    
    
    
    
22. PETERS S, Dafni U, Boyer M, De Ruysscher D, et al
    Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
    Ann Oncol. 2019 Jan 8. pii: 5280724. doi: 10.1093.
    PubMed     Text format    
    
    
    December 2018
23. WANG Y, Jiang T, Qin Z, Jiang J, et al
    HER2 exon 20 insertions in Non-Small Cell Lung Cancer are Sensitive to the Irreversible Pan-HER Receptor Tyrosine Kinase Inhibitor Pyrotinib.
    Ann Oncol. 2018 Dec 31. pii: 5267836. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
24. WU YL, Planchard D, Lu S, Sun H, et al
    Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
    Ann Oncol. 2018 Dec 28. pii: 5265324. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    October 2018
25. WAN Y, Liu B, Lei H, Zhang B, et al
    Nanoscale Extracellular Vesicle-Derived DNA is Superior to Circulating Cell Free DNA for Mutation Detection in Early-Stage Non-Small Cell Lung Cancer.
    Ann Oncol. 2018 Oct 18. pii: 5136413. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
26. PLANCHARD D, Popat S, Kerr K, Novello S, et al
    Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018;29.
    PubMed     Text format    
    
    
    September 2018
27. GADGEEL S, Peters S, Mok T, Shaw AT, et al
    Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
    Ann Oncol. 2018 Sep 12. pii: 5095692. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
28. TANIGUCHI Y, Takeda M, Tamiya A, Kasai T, et al
    Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small cell lung cancer.
    Ann Oncol. 2018 Sep 10. pii: 5094491. doi: 10.1093.
    PubMed     Text format    
    
    
    August 2018
29. KRON A, Alidousty C, Scheffler M, Merkelbach-Bruse S, et al
    Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
    Ann Oncol. 2018 Aug 23. pii: 5079835. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
30. COSTA DB
    TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.
    Ann Oncol. 2018 Aug 23. pii: 5110095. doi: 10.1093.
    PubMed     Text format    
    
    
    
31. THOMAS M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, et al
    Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study.
    Ann Oncol. 2018 Aug 20. pii: 5076437. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    July 2018
32. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
33. SORIA JC, Ho SN, Varella-Garcia M, Iafrate AJ, et al
    Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small cell lung cancer.
    Ann Oncol. 2018 Jul 13. pii: 5053587. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
34. COTTRELL TR, Thompson ED, Forde PM, Stein JE, et al
    Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC).
    Ann Oncol. 2018 Jul 6. pii: 5049993. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
35. RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
    Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
    Ann Oncol. 2018 Jul 3. pii: 5048419. doi: 10.1093.
    PubMed     Text format    
    
    
    June 2018
36. BONOMI PD, Gandara D, Hirsch FR, Kerr KM, et al
    Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
    Ann Oncol. 2018 Jun 14. pii: 5037893. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    May 2018
37. GERBER DE, Horn L, Boyer M, Sanborn R, et al
    Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
    Ann Oncol. 2018 May 14. pii: 4996069. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    April 2018
38. PINATO DJ, Kythreotou A, Mauri FA, Suardi E, et al
    Functional immune characterization of HIV-associated non-small cell lung cancer.
    Ann Oncol. 2018 Apr 20. pii: 4979448. doi: 10.1093.
    PubMed     Text format    
    
    
    
39. NOVELLO S, Mazieres J, Oh IJ, de Castro J, et al
    Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
    Ann Oncol. 2018 Apr 14. pii: 4970555. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
40. WANG H, Agulnik J, Kasymjanova G, Wang A, et al
    Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.
    Ann Oncol. 2018 Apr 12. pii: 4969231. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
41. MULLER DC, Hodge AM, Fanidi A, Albanes D, et al
    No association between circulating concentrations of vitamin D and risk of lung cancer: An analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3).
    Ann Oncol. 2018 Apr 2. pii: 4958387. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
42. DACIC S
    Time is up for PD-L1 testing standardization in lung cancer.
    Ann Oncol. 2018;29:791-792.
    PubMed     Text format    
    
    
    March 2018
43. DEROSA L, Hellmann MD, Spaziano M, Halpenny D, et al
    Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer.
    Ann Oncol. 2018 Mar 30. pii: 4956695. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
44. TAO MH, Chen S, Freudenheim JL, Cauley JA, et al
    Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
    Ann Oncol. 2018 Mar 29. pii: 4956655. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    February 2018
45. MCCOACH CE, Blumenthal GM, Zhang L, Myers A, et al
    Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.
    Ann Oncol. 2018 Feb 26. pii: 4909805. doi: 10.1093.
    PubMed     Text format    
    
    
    
46. VOKES EE, Ready N, Felip E, Horn L, et al
    Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
    Ann Oncol. 2018 Feb 2. pii: 4835443. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    January 2018
47. ADAM J, Le Stang N, Rouquette I, Cazes A, et al
    Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer.
    Ann Oncol. 2018 Jan 16. pii: 4812668. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
48. LI YS, Jiang BY, Yang JJ, Zhang XC, et al
    Unique Genetic Profiles from Cerebrospinal Fluid Cell-free DNA in Leptomeningeal Metastases of EGFR-mutant Non-Small Cell Lung Cancer: A New Medium of Liquid Biopsy.
    Ann Oncol. 2018 Jan 15. pii: 4810473. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
49. LAVOLE A, Guihot A, Veyri M, Lambotte O, et al
    PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?
    Ann Oncol. 2018 Jan 15. pii: 4810471. doi: 10.1093.
    PubMed     Text format    
    
    
    
50. GUIBERT N, Hu Y, Feeney N, Kuang Y, et al
    Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
    Ann Oncol. 2018 Jan 9. pii: 4794870. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
51. GHORANI E, Rosenthal R, McGranahan N, Reading JL, et al
    Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
    Ann Oncol. 2018;29:271-279.
    PubMed     Text format     Abstract available
    
    
    
52. ILIE M, Szafer-Glusman E, Hofman V, Chamorey E, et al
    Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
    Ann Oncol. 2018;29:193-199.
    PubMed     Text format     Abstract available
    
    
    
53. RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
    Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
    Ann Oncol. 2018;29.
    PubMed     Text format     Abstract available
    
    
    December 2017
54. KORDBACHEH T, Honeychurch J, Blackhall F, Faivre-Finn C, et al
    Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.
    Ann Oncol. 2017 Dec 22. pii: 4772556. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
55. GUIHOT A, Marcelin AG, Massiani MA, Samri A, et al
    Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
    Ann Oncol. 2017 Dec 1. pii: 4677259. doi: 10.1093.
    PubMed     Text format    
    
    
    
56. BI N, Liang J, Wang L
    Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'.
    Ann Oncol. 2017;28:3101-3103.
    PubMed     Text format    
    
    
    November 2017
57. YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
    Nivolumab in non-small cell lung cancer with EGFR mutation.
    Ann Oncol. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format    
    
    
    
58. EK L, Gezelius E, Bergman B, Bendahl PO, et al
    Randomized Phase III Trial of Low Molecular Weight Heparin Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: the RASTEN Trial.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
59. HAYASHI H, Mitsudomi T
    S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?
    Ann Oncol. 2017;28:2627-2629.
    PubMed     Text format    
    
    
    October 2017
60. OTSUBO K, Seki N, Nakanishi Y, Okamoto I, et al
    Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small cell lung cancer.
    Ann Oncol. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format    
    
    
    
61. ULAHANNAN D, Khalifa J, Faivre-Finn C, Lee SM, et al
    Emerging treatment paradigms in brain metastasis in non-small cell lung cancer: an overview of the current landscape and challenges ahead.
    Ann Oncol. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
62. SORIA JC, Fulop A, Maciel C, Fischer JR, et al
    SELECT-2: a Phase II, double-blind, randomised, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment for patients with advanced or metastatic non-small cell lung cancer.
    Ann Oncol. 2017 Oct 3. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
63. MARTINEZ-MARTI A, Felip E, Matito J, Mereu E, et al
    Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Ann Oncol. 2017;28:2451-2457.
    PubMed     Text format     Abstract available
    
    
    
64. CALVO E, Moreno V, Flynn M, Holgado E, et al
    Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Ann Oncol. 2017;28:2559-2566.
    PubMed     Text format     Abstract available
    
    
    September 2017
65. NOKIHARA H, Lu S, Mok TSK, Nakagawa K, et al
    Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
66. WEBER S, Wolkewitz M, Schumacher M
    Analyzing the impact of Depth of Response on Survival in patients with metastatic non-small cell lung cancer.
    Ann Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format    
    
    
    
67. ARGIRIS A, Lee JW, Stevenson J, Sulecki MG, et al
    Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3508).
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
68. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
    Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    
    
    
    
69. KATAKAMI N, Felip E, Spigel DR, Kim JH, et al
    A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
    Ann Oncol. 2017;28:2241-2247.
    PubMed     Text format     Abstract available
    
    
    
70. ITO M, Fujiwara S, Fujimoto D, Mori R, et al
    Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient.
    Ann Oncol. 2017;28:2318-2319.
    PubMed     Text format    
    
    
    
71. MANAPOV F, Eze C
    Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.
    Ann Oncol. 2017;28:2319-2320.
    PubMed     Text format    
    
    
    August 2017
72. SAAD ED, Buyse M
    Editorial on "Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy".
    Ann Oncol. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format    
    
    
    
73. KOLLER M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, et al
    An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients.
    Ann Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
74. MAENO K, Fukuda S, Oguri T, Niimi A, et al
    Nivolumab-induced asthma in a patient with non-small cell lung cancer.
    Ann Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format    
    
    
    
75. MCCOACH CE, Blumenthal GM, Zhang L, Myers A, et al
    Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy.
    Ann Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
76. CURIONI-FONTECEDRO A, Ickenberg C, Franzen D, Rogler G, et al
    Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
    Ann Oncol. 2017;28:2040-2041.
    PubMed     Text format    
    
    
    July 2017
77. LEDUC C, Merlio JP, Besse B, Blons H, et al
    Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
    Ann Oncol. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
78. HENTRICH M, Schipek-Voigt K, Jager H, Schulz S, et al
    Nivolumab in HIV-related non-small-cell lung cancer.
    Ann Oncol. 2017 Jul 6. doi: 10.1093.
    PubMed     Text format    
    
    
    
79. 
    Appendix 8: Metastatic non-small-cell lung cancer (2): eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    Ann Oncol. 2017;28.
    PubMed     Text format    
    
    
    
80. 
    Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    Ann Oncol. 2017;28.
    PubMed     Text format    
    
    
    
81. POSTMUS PE, Kerr KM, Oudkerk M, Senan S, et al
    Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2017;28.
    PubMed     Text format    
    
    
    
82. BOLAND JM, Mansfield AS, Roden AC
    Pulmonary sarcomatoid carcinoma-a new hope.
    Ann Oncol. 2017;28:1417-1418.
    PubMed     Text format    
    
    
    
83. PECUCHET N, Vieira T, Rabbe N, Antoine M, et al
    Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.
    Ann Oncol. 2017;28:1597-1604.
    PubMed     Text format     Abstract available
    
    
    
84. LESAFFRE E, Edelman MJ, Hanna NH, Park K, et al
    Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.
    Ann Oncol. 2017;28:1419-1426.
    PubMed     Text format     Abstract available
    
    
    June 2017
85. TOMITA Y, Sueta D, Kakiuchi Y, Saeki S, et al
    Acute Coronary Syndrome as a Possible Immune-Related Adverse Event in a Lung Cancer Patient Achieving a Complete Response to Anti-PD-1 Immune Checkpoint Antibody.
    Ann Oncol. 2017 Jun 23. doi: 10.1093.
    PubMed     Text format    
    
    
    
86. LINDSAY CR, Faugeroux V, Michiels S, Pailler E, et al
    A Prospective Examination of Circulating Tumor Cell Profiles in Non-Small Cell Lung Cancer Molecular Subgroups.
    Ann Oncol. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
87. DEVARAKONDA S, Govindan R
    TRAC(ERx)-ing Lung Cancer Evolution.
    Ann Oncol. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format    
    
    
    
88. SANMAMED MF, Perez-Gracia JL, Schalper KA, Fusco JP, et al
    Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients.
    Ann Oncol. 2017 Jun 8. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
89. DURUISSEAUX M, Mc Leer-Florin A, Moro-Sibilot D, Cadranel J, et al
    Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy?
    Ann Oncol. 2017;28:1401.
    PubMed     Text format    
    
    
    
90. KIM HR, Kang HN, Shim HS, Kim EY, et al
    Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
    Ann Oncol. 2017;28:1250-1259.
    PubMed     Text format     Abstract available
    
    
    May 2017
91. CHRISTOPOULOS P, Engel-Riedel W, Grohe C, Kropf-Sanchen C, et al
    Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
    Ann Oncol. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
92. CURROW D, Temel JS, Abernethy A, Milanowski J, et al
    ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia.
    Ann Oncol. 2017 May 4. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
93. GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.
    Ann Oncol. 2017;28:1084-1089.
    PubMed     Text format     Abstract available
    
    
    
94. ZHANG L, Ye Y, Tu H, Hildebrandt MA, et al
    MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk.
    Ann Oncol. 2017;28:1124-1129.
    PubMed     Text format     Abstract available
    
    
    
95. BESSE B, Mazieres J, Ribassin-Majed L, Barlesi F, et al
    Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
    Ann Oncol. 2017;28:1078-1083.
    PubMed     Text format     Abstract available
    
    
    April 2017
96. DHILLON HM, Bell ML, van der Ploeg HP, Turner JD, et al
    Impact of Physical Activity on Fatigue and Quality of Life in People with Advanced Lung Cancer: a Randomised Controlled Trial.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
97. HARATANI K, Hayashi H, Tanaka T, Kaneda H, et al
    Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
98. SEO S, Woo CG, Lee DH, Choi J, et al
    The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small cell lung cancer.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format    
    
    
    
99. FERRONIKA P, van den Bos H, Taudt A, Spierings DCJ, et al
    Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small cell lung cancer patient.
    Ann Oncol. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format    
    
    
    
100. ZHANG Y, Zhang L, Li R, Chang DW, et al
     Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.
     Ann Oncol. 2017 Apr 5. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
101. REMON J, Caramella C, Jovelet C, Lacroix L, et al
     Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
     Ann Oncol. 2017;28:784-790.
     PubMed     Text format     Abstract available
     
     
     March 2017
102. KATAOKA Y, Ebi N, Fujimoto D, Hara S, et al
     Prior radiotherapy does not predict nivolumab response in non-small cell lung cancer: a retrospective cohort study.
     Ann Oncol. 2017 Mar 20. doi: 10.1093.
     PubMed     Text format    
     
     
     
103. KIM ST, Kim SY, Klempner SJ, Yoon J, et al
     Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
     Ann Oncol. 2017;28:547-554.
     PubMed     Text format     Abstract available
     
     
     
104. CHANDRANI P, Prabhash K, Prasad R, Sethunath V, et al
     Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
     Ann Oncol. 2017;28:597-603.
     PubMed     Text format     Abstract available
     
     
     February 2017
105. ZOU T, Awad MM
     More valuable than platinum: first-line pembrolizumab in advanced stage non-small cell lung cancer.
     Ann Oncol. 2017 Feb 27. doi: 10.1093.
     PubMed     Text format    
     
     
     
106. GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
     Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomised trial.
     Ann Oncol. 2017 Feb 21. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
107. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
     European cancer mortality predictions for the year 2017, with focus on lung cancer.
     Ann Oncol. 2017 Feb 21. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
108. PAZ-ARES L, Tan EH, O'Byrne K, Zhang L, et al
     Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
     Ann Oncol. 2017;28:270-277.
     PubMed     Text format     Abstract available
     
     
     
109. YOSHIOKA H, Katakami N, Okamoto H, Iwamoto Y, et al
     A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
     Ann Oncol. 2017;28:285-291.
     PubMed     Text format     Abstract available
     
     
     
110. REMON J, Soria JC
     Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
     Ann Oncol. 2017;28:196-198.
     PubMed     Text format    
     
     
     
111. YANG TO, Cairns BJ, Reeves GK, Green J, et al
     Cancer risk among 21st century blood transfusion recipients.
     Ann Oncol. 2017;28:393-399.
     PubMed     Text format     Abstract available
     
     
     
112. YU HA, Sima C, Feldman D, Liu LL, et al
     Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
     Ann Oncol. 2017;28:278-284.
     PubMed     Text format     Abstract available
     
     
     January 2017
113. KADARA H, Choi M, Zhang J, Parra ER, et al
     Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
     Ann Oncol. 2017;28:75-82.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: